



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

13 May 2022
EMA/CHMP/259930/2022
Human Medicines Division

Committee for medicinal products for human use (CHMP) PROM¹ minutes for the meeting on 10 May 2022

Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes

10 May 2022, 09:00–13:20, virtual meeting/room 08-A

Disclaimers

Some of the information contained in this document is considered commercially confidential or sensitive and therefore not disclosed.

Of note, agendas and minutes are working documents primarily designed for CHMP members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda/minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

¹ The CHMP Preparatory and Organisational Matters (PROM) is a meeting to discuss CHMP organisational matters and other topics in preparation for the CHMP Plenary meeting. It is a virtual meeting, which usually takes place on Monday before the CHMP Plenary meeting. CHMP members, working party chairs and national experts together with EMA staff are participating in this forum. Depending on the nature of the issue and availability of documents and experts some PROM topics can be discussed at the CHMP Plenary.



Table of contents

1.	Agenda and Minutes	4
1.1.	Welcome and declarations of interest of members, alternates and experts.....	4
1.2.	Adoption of agenda.....	4
1.3.	Adoption of the minutes	4
2.	Non-therapeutic-area-specific working parties	4
2.1.	Patients and Consumers Working Party (PCWP) Healthcare Professionals Working Party (HCPWP)	4
2.2.	Biologics Working Party (BWP)	4
2.3.	Quality Working Party (QWP)	4
2.4.	Safety Working Party (SWP).....	5
2.5.	Non-clinical Working Party (NcWP)	5
2.6.	Biosimilar Medicinal Product Working Party (BMWP)	6
2.7.	Methodology Working Party (MWP).....	6
3.	Therapeutic-area-specific working parties and SAGs	6
3.1.	Haematology Working Party (HaemWP).....	6
3.2.	Central Nervous System Working Party (CNSWP)	6
3.3.	Cardiovascular Working Party (CVSWP)	6
3.4.	Infectious Diseases Working Party (IDWP)	6
3.5.	Oncology Working Party (ONCWP)	7
3.6.	Rheumatology/Immunology Working Party (RIWP)	7
3.7.	Vaccines Working Party (VWP).....	8
3.8.	Scientific Advisory Groups (SAGs)	8
4.	Drafting groups	8
4.1.	Excipients Drafting Group	8
4.2.	Gastroenterology Drafting Group (GDG)	8
4.3.	Geriatric Expert Group (GEG).....	8
4.4.	Radiopharmaceuticals Drafting Group (RadDG).....	8
4.5.	Respiratory Drafting Group (RDG)	8
4.6.	Diabetes Drafting Group	8
5.	Harmonisation and consistency groups	9
5.1.	International Council on Harmonisation (ICH)	9
5.2.	Guideline Consistency Group (GCG).....	9
5.3.	Summary of product characteristics Advisory Group	9

6.	Joint groups and collaboration with other Scientific committees	9
6.1.	Joint CVMP/CHMP ad-hoc expert group on the application of the 3Rs (replacement, reduction and refinement) in the regulatory testing of medicinal products (J 3RsWG)	9
6.2.	Joint CHMP/CVMP/CMDh/CMDv Working Group on Active Substance Master File Procedures (ASMF WG)	9
6.3.	Collaboration with other Scientific committees and Working Groups.....	10
7.	Regulatory/Organisational matters	10
7.1.	Regulatory Issues/new legislation	10
7.2.	CHMP organisation/templates	11
8.	Product development support	12
8.1.	Scientific Advice Working Party (SAWP).....	12
8.2.	Innovation Task Force	12
9.	Product related topics	12
9.1.	Preview CHMP Plenary.....	12
9.2.	COVID-19 ongoing and upcoming procedures	12
10.	Any Other Business	13
10.1.	Rapporteurships	13
10.2.	Update on the upcoming proof-of-concept raw data pilot.....	13
10.3.	Embedding the outcome of GCP inspections into the B/R assessment and modernisation of the inspection process	13
10.4.	(Vice)chair presentations for Working Parties.....	13
10.5.	RMP Publications – future activities	13
10.6.	CHMP opinion on an interchangeability of biosimilars statement	14
10.7.	CRISP - CHMP's Regular Information on Selected Procedures	14
11.	List of Participants	15

1. Agenda and Minutes

1.1. Welcome and declarations of interest of members, alternates and experts

In accordance with the Agency's policy on handling of declarations of interests of scientific Committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting as well as the draft agenda of the plenary meeting, the Committee Secretariat announced the restricted involvement of some Committee members, alternates and experts for concerned agenda topics.

Participants were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared. Restrictions applicable to this meeting are captured in the list of participants included in the minutes.

1.2. Adoption of agenda

The CHMP adopted the PROM agenda for the 10 May 2022 meeting.

1.3. Adoption of the minutes

CHMP PROM Minutes of 10 May 2022 meeting will be adopted at the May CHMP plenary.

2. Non-therapeutic-area-specific working parties

2.1. Patients and Consumers Working Party (PCWP) Healthcare Professionals Working Party (HCPWP)

No topics

2.2. Biologics Working Party (BWP)

Chair: Sol Ruiz

2.2.1. Agenda and minutes

- Draft agenda of BWP meeting to be held virtually on 10-12 May 2022
- Final minutes of BWP meeting held virtually on 14-16 March 2022

Action: For information

The CHMP noted the agenda and the minutes.

2.3. Quality Working Party (QWP)

Chair: Blanka Hirschlerova

2.3.1. Agenda

- Final Agenda for QWP-CT meeting held by Webex on 13 April 2022

Action: For information

The CHMP noted the agenda.

2.4. Safety Working Party (SWP)

Chair: Susanne Brendler-Schwaab

2.4.1. Minutes

- Final minutes for SWP meeting held by teleconference on 13 April 2022

Action: For information

The CHMP noted the minutes.

2.4.2. SWP positions on requests on new nitrosamines

- SWP position on NTP (7-nitroso-3-(trifluoromethyl)-5,6,7,8-tetrahydro[1,2,4]triazolo-[4,3- a]pyrazine) acceptable intake in Sitagliptin
- SWP position on N-nitrosonortryptiline (NNORT) acceptable intake
- SWP position on N-nitroso diisopropanolamine (NDIPLA) acceptable intake
- SWP position on N-nitrosorasagilene acceptable intake

Action: For adoption

The CHMP adopted the SWP positions on the new nitrosamines.

2.5. Non-clinical Working Party (NcWP)

Chairs: Susanne Brendler-Schwaab and Karen van Malderen

2.5.1. Agenda

- Draft agenda for NcWP meeting to be held by teleconference on 10-11 May 2022

Action: For information

The CHMP noted the agenda.

2.5.2. CMDh requests to SWP/NcWP on new nitrosamines

- The CMDh requests that the SWP/NcWP determines the acceptable intake for N-nitroso-metoprolol based on lifetime daily exposure including information on the points of departure and methodology used.
- The CMDh requests that the SWP/NcWP determines the acceptable intake for N-nitroso-aryl piperazine based on lifetime daily exposure including information on the points of departure and methodology used.

- The CMDh requests that the SWP/NcWP determines the acceptable intake for N-Nitrosodiethanolamine (NDELA) based on lifetime daily exposure including information on the points of departure and methodology used.

Action: For adoption

The CHMP endorsed the CMDh questions to the Non-clinical Working Party.

2.6. Biosimilar Medicinal Product Working Party (BMWP)

No topics

2.7. Methodology Working Party (MWP)

Chairs: Christian Roes and Kristin Karlsson

2.7.1. Agenda and minutes

- Agenda and Minutes for MWP meeting held by teleconference on 28 April 2022

Action: For information

The CHMP noted the agenda and the minutes.

2.7.2. Nominations for additional expertise for MWP

Presentation of nominations received.

Action: For discussion

The CHMP noted the nominations received for the additional expertise for the MWP. The CHMP will be further updated with the proposed members for endorsement at one of the next meetings.

3. Therapeutic-area-specific working parties and SAGs

3.1. Haematology Working Party (HaemWP)

No topics

3.2. Central Nervous System Working Party (CNSWP)

No topics

3.3. Cardiovascular Working Party (CVSWP)

No topics

3.4. Infectious Diseases Working Party (IDWP)

Chair: Maria Jesus Fernandez Cortizo

3.4.1. [Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections, \(CPMP/EWP/558/95 Rev 3\)](#)

This Guideline merges, revises and adds to the guidance previously included in the *Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections* (CPMP/EWP/558/95 Rev 2) and the Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections (EMA/CHMP/351889/2013).

Action: For adoption

The CHMP adopted the guideline.

3.4.2. [Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections to address paediatric-specific clinical data requirements \(EMA/CHMP/187859/2017\)](#)

This addendum to the *Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections* (CPMP/EWP/558/95 rev 3) has been developed to provide guidance on clinical development programmes that are required to support the authorisation of antibacterial agents for treatment of infectious diseases in paediatric patients.

Action: For adoption

The CHMP adopted the Addendum.

3.5. **Oncology Working Party (ONCWP)**

Chairs: Pierre Demolis and Sigrid Klaar

3.5.1. [Call for nominations ESEC Oncology](#)

The membership of the ESEC will be composed of experts that are assessors working for a National Competent Authority, members of the different working parties with a special interest or expertise in oncology and members from academia in institutions/universities that are relevant for the Oncology ESEC. The experts will need to be nominated by a Committee member (COMP, PDCO, PRAC, CAT and CHMP). Committee members, Oncology WP members and SAG Oncology members can request access to the ESEC automatically.

The expert will need to provide their CV and a valid DoI to be included in the expert database. Therefore, any expert who is in the expert database can be proposed to be part of the ESEC.

The appointment of the ESEC member will be agreed by the Oncology Working Party and a list of new memberships will be presented to the CHMP for adoption.

Action: For endorsement

The CHMP endorsed the call for nominations for the Oncology European Scientific Expert Group. The CHMP also noted the draft rules of procedure of the ESEC.

3.6. **Rheumatology/Immunology Working Party (RIWP)**

No topics

3.7. Vaccines Working Party (VWP)

No topics

3.8. Scientific Advisory Groups (SAGs)

No topics

4. Drafting groups

4.1. Excipients Drafting Group

No topics

4.2. Gastroenterology Drafting Group (GDG)

No topics

4.3. Geriatric Expert Group (GEG)

No topics

4.4. Radiopharmaceuticals Drafting Group (RadDG)

No topics

4.5. Respiratory Drafting Group (RDG)

No topics

4.6. Diabetes Drafting Group

4.6.1. Reflection Paper on the data required in confirmatory studies of medicinal products for the treatment of type 2 diabetes (EMA/240473/2022)

The CHMP has agreed previously that the revision of the "Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus" CPMP/EWP/1080/00 Rev. 2" can be continued and the Diabetes drafting Group was established in 2021.

Based on recent discussions in the CHMP, it has been decided to consider (in addition to implementing external comments) if the data requirements with respect to confirmatory studies for certain claims in the wording of the therapeutic indication would benefit from revisions. In addition to internal discussions within the regulatory system, it was considered that input from external stakeholders would be valuable. The draft Reflection Paper tabled is the proposal from the Group that is currently put for the discussion at the CHMP.

Action: For adoption

The CHMP adopted the reflection paper for release for a 3-month public consultation.

5. Harmonisation and consistency groups

5.1. International Council on Harmonisation (ICH)

5.1.1. Adoption of guidelines

ICH Guideline M7(R2): Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk - Questions and Answers. Implementation 6 months after publication.

Action: For adoption

The CHMP adopted the ICH M7(R2) Questions and Answers document.

5.2. Guideline Consistency Group (GCG)

Chair(s): Vacant

5.2.1. Second call for volunteers to join the Guideline Consistency Group

Call for volunteers (CHMP, SAWP members and experienced assessors) to join the group. Nominations to be sent 20 May 2022, with a summary of experience and expertise.

Action: For discussion

The CHMP noted the call for more members and a chair of the GCG. The Committee endorsed Maria Grazia Evandri and Janet Koenig as new members.

5.3. Summary of product characteristics Advisory Group

5.3.1. SmPC Advisory Group Membership update

CHMP representative to join the SmPC Advisory Group.

Action: For adoption

The CHMP endorsed Anna Baumann (BfArM) as CHMP representative of the SmPC Advisory Group.

6. Joint groups and collaboration with other Scientific committees

6.1. Joint CVMP/CHMP ad-hoc expert group on the application of the 3Rs (replacement, reduction and refinement) in the regulatory testing of medicinal products (J 3RsWG)

No topics

6.2. Joint CHMP/CVMP/CMDh/CMDv Working Group on Active Substance Master File Procedures (ASMF WG)

No topics

6.3. Collaboration with other Scientific committees and Working Groups

6.3.1. PRAC report to CHMP

Chair: Sabine Straus

Summary of recommendations and advice of PRAC meeting held on 2-5 May 2022.

Action: For information

The CHMP noted the summary of recommendations and advice.

6.3.2. Call for volunteer for COMP expert meeting

Chair: Violeta Stoyanova-Beninska

Request for volunteer to take part in the clinical and patients consultation COMP expert meeting about orphan conditions in Inherited Retinal Dystrophies (IRD) on behalf of the CHMP.

Action: For information

The CHMP noted the COMP discussion paper on Inherited Retinal Dystrophies and Orphan Designations. In order to develop the new options an expert consultation was proposed. The CHMP noted the call for a volunteer to participate on behalf of CHMP.

6.3.3. Guideline on core SmPC, Labelling and Package Leaflet for advanced therapy medicinal products (ATMPs) containing genetically modified cells EMA/CAT/CHMP/158266/2021

In October 2020, to account for inconsistencies in the product information of ATMPs containing genetically modified cells, the CAT, in agreement with the CAT EC representative and QRD group initiated a review of the QRD template to introduce additional wording and guidance specific to these products. Due to the extent of changes required, the work has culminated in the creation of a core SmPC, labelling and package leaflet for ATMPs containing genetically modified cells, to be read in conjunction with the SmPC guideline and QRD template.

After a 3-month external consultation period, the core SmPC has been agreed with CAT/QRD and EC and is brought to the CHMP for adoption prior to publication, together with the overview of comments.

Action: For adoption

The CHMP adopted the Guideline.

7. Regulatory/Organisational matters

7.1. Regulatory Issues/new legislation

7.1.1. Revision of the EU pharmaceutical legislation

Final CHMP position on new Pharmaceutical Strategy.

Action: For adoption

The CHMP noted the update and adopted CHMP position on the revision of the EU pharmaceutical legislation.

7.2. CHMP organisation/templates

7.2.1. CHMP learnings

Collection, discussion and recording of CHMP learnings.

CHMP: Outi Mäki-Ikola

Action: For discussion

The CHMP learnings will be further updated and agreed at the June PROM.

7.2.2. Return to Committees face-to-face meetings

Update on the preparation for holding the May and July CHMP plenary meetings as face-to-face/Webex hybrid.

Action: For information

The CHMP welcomed the opportunity to meet face-to-face at the May and July CHMP Plenary meetings.

In order to facilitate the hotel and travel booking for the July F2F meeting, the invitations will be sent earlier to the CHMP members.

The EMA health and safety video was shown to the delegates. For those delegates who did not have the opportunity to watch the H&S video, please have a look at the (longer) delegates induction video before coming to the EMA building.

7.2.3. CHMP co-opted membership

The 3-year co-opted member mandate for Christian Gartner comes to an end on 23.06.2022. His area of expertise is medical statistics.

The 3-year co-opted member mandate for Sol Ruiz comes to an end on 21.07.2022. Her area of expertise is quality and safety (biological), with expertise in advanced therapies (gene, cell and tissue therapies).

CHMP decided at the March PROM that the two co-opted member positions should be filled again. A discussion is expected on the area(s) of expertise for the two co-opted member positions.

Action: For discussion

The CHMP discussed the areas of expertise for the two co-opted member positions and agreed by consensus that there is the need for Medical statistics and Quality and safety (biological), with expertise in advanced therapies (gene, cell and tissue therapies).

Two separate calls for nomination will be issued soon after the PROM meeting.

8. Product development support

8.1. Scientific Advice Working Party (SAWP)

Chair: Paolo Foggi

8.1.1. Appointment of CHMP peer review for SA

Action: For information

The CHMP noted the report.

8.1.2. Nomination of new members and alternates to the Scientific Advice Working Party

Nomination of new SAWP members and alternates.

Required areas of expertise: non-clinical, oncology, biosimilars, vaccines.

Action: For endorsement

The CHMP noted the nominations received and endorsed the following new SAWP members and alternates:

Member: Mette Linnert Jensen, Alternate: Martin Bronislaw Oleksiewicz

Member: Juha Kolehmainen, Alternate: Anja Schiel

Member: Cristina Migali, Alternate: Adriana Ammassari

8.2. Innovation Task Force

No topics

9. Product related topics

9.1. Preview CHMP Plenary

CHMP: Harald Enzmann

Action: For information

The CHMP Chair flagged some procedures on the agenda of the upcoming plenary.

9.2. COVID-19 ongoing and upcoming procedures

List of currently ongoing and upcoming (imminently, i.e. expected within the next 2 months) applications for COVID-19 vaccines and therapeutics.

Action: For information

CHMP noted the COVID-19 ongoing and upcoming procedures.

10. Any Other Business

10.1. Rapporteurships

Update.

Action: For information

The CHMP noted the update.

10.2. Update on the upcoming proof-of-concept raw data pilot

Update on the proof-of-concept raw data pilot including information on how to participate in the pilot. The pilot, which is expected to start in Q3 2022, will analyse individual patient data in electronic structured format (raw data) from selected marketing authorisation applications. The pilot aims to generate relevant learnings about accessing and analysing raw data during the assessment process.

The proof-of-concept raw data pilot is part of EMA's Lifecycle Regulatory Submissions Raw Data project, which is focusing on utilising raw data to support regulatory decision-making and was listed as an action in CHMP's work plan for 2022.

Action: For discussion

The CHMP noted the information.

10.3. Embedding the outcome of GCP inspections into the B/R assessment and modernisation of the inspection process

Action: For discussion

The CHMP noted the update.

10.4. (Vice)chair presentations for Working Parties

The candidates for the remaining chair/vice-chair positions of the working parties are asked to present themselves at the PROM. The election is planned at the May CHMP plenary meeting.

Nominations received.

Action: For discussion

The CHMP noticed the presentations by the candidates. The election is scheduled for the May plenary meeting.

10.5. RMP Publications – future activities

Experience with Covid-19 related products RMP publication is already gained and EMA would like to further progress with publishing the RMPs of new active substances (Art 8.3 of DIR). The RMP summary is published for all products; RMP (main body and Annexes 4 and 6, as single PDF) will replace the RMP summary (in EPAR), in due course. This is aiming at further increasing transparency of safety information for public/stakeholders.

Action: For information

The CHMP noted the update that for MAAs with an opinion from July 2022 CHMP onwards, the RMP will be published in the EPAR.

10.6. CHMP opinion on an interchangeability of biosimilars statement

Interchangeability refers to the possibility of exchanging one medicine for another medicine that is expected to have the same clinical effect. From a scientific perspective, once a biosimilar is approved in the EU it is considered interchangeable, which may concern replacing a reference product with a its biosimilar (or vice versa) or replacing one biosimilar with another biosimilar of the same reference product. Decisions regarding substitution (the practice of dispensing one medicine instead of another medicine without consulting the prescriber), are not within the remit of the EMA and are managed by individual member states.

Action: For adoption

The CHMP adopted the interchangeability of biosimilars statement.

10.7. CRISP - CHMP's Regular Information on Selected Procedures

Action: For information

The CHMP noted an update on CRISP, which is part of the CHMP workplan. Examples of the monthly highlights as well as an example for a specific public communication on Oncology was presented.

11. List of Participants

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda and for which restrictions apply
Harald Enzmann	Chair	Germany	No interests declared	
Andrea Laslop	Member	Austria	No interests declared	
Daniela Philadelphy	Alternate	Austria	No interests declared	
Karin Janssen van Doorn	Alternate	Belgium	No interests declared	
Margareta Bego	Member	Croatia	No interests declared	
Selma Arapovic Dzakula	Alternate	Croatia	No interests declared	
Helena Panayiotopoulou	Member	Cyprus	No interests declared	
Ondřej Slanař	Member	Czechia	No restrictions applicable to this meeting	
Tomas Radimersky	Alternate	Czechia	No interests declared	
Thalia Marie Estrup Blicher	Member	Denmark	No restrictions applicable to this meeting	
Edward Laane	Alternate	Estonia	No restrictions applicable to this meeting	
Outi Mäki-Ikola	Member	Finland	No restrictions applicable to this meeting	
Johanna Lähteenvuo	Alternate	Finland	No interests declared	
Alexandre Moreau	Member	France	No interests declared	
Jean-Michel Race	Alternate	France	No interests declared	
Martina Weise	Member	Germany	No restrictions applicable to this meeting	
Janet Koenig	Alternate	Germany	No interests declared	
Anastasia Mountaki	Alternate	Greece	No interests declared	
Robert Porszasz	Member	Hungary	No interests declared	
Agnes Gyurasics	Alternate	Hungary	No interests declared	
Hrefna Gudmundsdottir	Member	Iceland	No interests declared	
Jan Sjöberg	Alternate	Iceland	No interests declared	
Jayne Crowe	Member	Ireland	No interests declared	
Armando Genazzani	Member	Italy	No interests declared	
Maria Grazia Evandri	Alternate	Italy	No interests declared	
Elita Poplavska	Member	Latvia	No interests declared	
Romaldas Mačiulaitis	Member	Lithuania	No participation in final deliberations and voting	COVID-19 vaccines
Martine Trauffler	Member	Luxembourg	No interests declared	
Johann Lodewijk Hillege	Member	Netherlands	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda and for which restrictions apply
Paula Boudewina van Hennik	Alternate	Netherlands	No interests declared	
Ingrid Wang	Member	Norway	No interests declared	
Eva Skovlund	Alternate	Norway	No interests declared	
Ewa Balkowiec Iskra	Member	Poland	No interests declared	
Bruno Sepodes	Member (Vice-Chair)	Portugal	No interests declared	
Fatima Ventura	Alternate	Portugal	No participation in final deliberations and voting	COVID-19 vaccines
Simona Badoi	Member	Romania	No interests declared	
Dana Gabriela Marin	Alternate	Romania	No interests declared	
Francisek Drafi	Member	Slovakia	No interests declared	
Nevenka Trsinar Brodt	Alternate	Slovenia	No interests declared	
Maria Concepcion Prieto Yerro	Member	Spain	No interests declared	
Blanca Garcia-Ochoa	Alternate	Spain	No interests declared	
Kristina Dunder	Member	Sweden	No interests declared	
Filip Josephson	Alternate	Sweden	No interests declared	
Christian Gartner	Co-opted member	Austria	No interests declared	
Carla Torre	Co-opted member	Portugal	No interests declared	
Jan Mueller-Berghaus	Co-opted member	Germany	No interests declared	
Blanka Hirschlerova	Co-opted member	Czechia	No interests declared	
Vincent Gazin	Expert - via WebEx*	France	No interests declared	
Irene Bachmann	Expert - via WebEx*	Germany	No interests declared	
Ramla Hamada	Expert - via WebEx*	France	No interests declared	
Sabine Mayrhofer	Expert - via WebEx*	Germany	No interests declared	
Nora Cascante Estepa	Expert - via WebEx*	Germany	No interests declared	
Deirdre Mannion	Expert - via WebEx*	Denmark	No restrictions applicable to this meeting	
Maria Jesús Fernández Cortizo	Expert - via WebEx*	Spain	No interests declared	
Mair Powell	Expert - via WebEx*	Ireland	No interests declared	
Luca Santi	Expert - via WebEx*	Italy	No restrictions applicable to this meeting	
Martina Perini	Expert - via WebEx*	Italy	No restrictions applicable to this meeting	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda and for which restrictions apply
Paula Contreras Alarcón	Expert - via WebEx*	Spain	No participation in discussion, final deliberations and voting	Rinvoq - upadacitinib - EMEA/H/C/004760/X/0012/G
Maria Antonia Tudanca Pacios	Expert - via WebEx*	Spain	No restrictions applicable to this meeting	
Mas Parra Paloma	Expert - via WebEx*	Spain	No restrictions applicable to this meeting	
Martina Schuessler-Lenz	Expert - via WebEx*	Germany	No interests declared	
Maja Sommerfelt Grønvold	Expert - via WebEx*	Norway	No interests declared	
Adriana Ammassari	Expert - via WebEx*	Italy	No interests declared	
Susanne Hopner Rasmussen	Expert - via WebEx*	Denmark	No interests declared	
Elena Wolff-Holz	Expert - via WebEx*	Germany	No interests declared	
Valerie Lescrainier	Expert - via WebEx*	Belgium	No interests declared	
Meeting run with the help of EMA staff				

*Experts were evaluated against the product(s) they have been invited to talk about